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Abstract
Background: The antiviral action of interferon alpha targets the 5' untranslated region (UTR)
used by hepatitis C virus (HCV) to translate protein by an internal ribosome entry site (IRES)
mechanism. Although this sequence is highly conserved among different clinical strains,
approximately half of chronically infected hepatitis C patients do not respond to interferon therapy.
Therefore, development of small interfering RNA (siRNA) targeted to the 5'UTR to inhibit IRES
mediated translation may represent an alternative approach that could circumvent the problem of
interferon resistance.
Results: Four different plasmid constructs were prepared for intracellular delivery of siRNAs
targeting the stem loop II-III of HCV 5' UTR. The effect of siRNA production on IRES mediated
translation was investigated using chimeric clones between the gene for green fluorescence protein
(GFP) and IRES sequences of six different HCV genotypes. The siRNA targeted to stem loop II
effectively mediated degradation of HCV IRES mRNA and inhibited GFP expression in the case of
six different HCV genotypes, where as siRNAs targeted to stem loop III did not. Furthermore,
intracytoplasmic expression of siRNA into transfected Huh-7 cells efficiently degraded HCV
genomic RNA and inhibited core protein expression from infectious full-length infectious clones
HCV 1a and HCV 1b strains.
Conclusion: These in vitro studies suggest that siRNA targeted to stem-loop II is highly effective
inhibiting IRES mediated translation of the major genotypes of HCV. Stem-loop II siRNA may be a
good target for developing an intracellular immunization strategy based antiviral therapy to inhibit
hepatitis C virus strains that are not inhibited by interferon.
Background
Hepatitis C virus (HCV) is a major blood-borne human
pathogen [1]. It is estimated that more than 170 million
people worldwide have been infected with hepatitis C [2].
The majority of infected individuals develop life long
chronic infections since only a fraction of people infected
with HCV develop immunity and clear the virus infection
[3]. Chronic hepatitis C virus infection can results in long-
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standing inflammation in the liver, which can lead to liver
cirrhosis and hepatocellular carcinoma [4,5]. The only
therapy currently available for HCV infection is the com-
bination of interferon alpha and ribavirin. This therapy
can effectively clear the virus infection in only a fraction of
infected individuals. In the majority of patient infected
the virus either does not respond to therapy or relapses
when the therapy is discontinued [6-8]. Studies from our
laboratories and others suggest that interferon inhibits
hepatitis C virus replication by blocking it at the level of
IRES mediated translation [9]. Therefore, the develop-
ment of innovative approach to inhibit IRES may offer an
alternative therapy for chronic hepatitis C patients that are
non-responders to interferon.
HCV is a positive-stranded RNA virus that belonging to
the family Flaviviridae [10]. The HCV genome is approxi-
mately 9600 nucleotides in length and contains highly
conserved 5' and 3' untranslated regions (UTR). These
regions flanks a single large open reading frame (ORF)
that encodes a large poly-protein processed into three dif-
ferent structural and seven nonstructural proteins. [11].
The highly conserved 5' UTR and 3' UTR sequences are
required for both protein translation and virus replication
[12,13]. The replication cycle of HCV occurs in the cyto-
plasm of infected cells making an excellent target for
siRNA based antiviral development.
Since many individual cannot eradicate the virus infection
with interferon based combination therapy, there is great
interest to use this siRNA based antiviral strategy to treat a
chronic HCV infection. A number of laboratories includ-
ing our own have shown that siRNA targeted to the pro-
tein coding areas of HCV can inhibit virus replication and
expression [14-21]. However, these viral coding
sequences may not be the best target since they show sig-
nificant variation among different HCV genotypes as well
as virus sub-types. The nucleotide sequences of genomes
from HCV isolated from different parts of the world vary
considerably and are quite heterogeneous. Six major gen-
otypes and more than 50 sub-types of the HCV virus have
been described around the world. There are 30–50% vari-
ation in the nucleotide sequences among viral genotypes
and 15–30% among different sub-types [22,23]. Isolates
of HCV from a single patient can show 1–5% differences
in their nucleotide sequences. In the United States, 75% of
chronic hepatitis C cases belong to genotype 1a and 1b,
13–15% genotype 2a and 2b and 6–7% genotype 3a [24].
Genotype 1a and 1b is common in Western Europe. Gen-
otype 3 is most frequent in the Indian subcontinent. Gen-
otype 4 is the most common genotype in Africa and the
Middle East. Genotype 5 is found in South Africa. Geno-
type 6 is found in Hong Kong and Southeast Asia [25].
Therefore, selection of siRNA targeted to a highly con-
served region may be appropriate for developing a
rational antiviral strategy against different HCV strains.
In this study, we designed the most effective siRNAs tar-
gets in the highly conserved 5' UTR of the HCV genome.
Their antiviral effect on IRES mediated translation was
evaluated using sub-genomic clones and full-length infec-
tious clones. We showed here that siRNA targeted to a
unique location in the stem loop-II of 5' UTR inhibits
IRES function of different genotypes and silence expres-
sion of multiple HCV genotypes.
Results
Intracellular delivery of siRNA inhibits GFP expression 
from HCV-IRES
Four different siRNAs (siRNA-74, siRNA-174, siRNA-207
and siRNA-245) targeting the 5' untranslated region
(5'UTR) of hepatitis C virus genome were selected. The
location and nucleotide sequence representing the RNAi
target sites with respect to the predicted secondary struc-
ture of HCV IRES are shown in Fig. 1. pSuper-retro vector
was used for intracellular production of siRNA in a liver
derived cell line. Efficient transcription of siRNA from this
vector occurs by host cell RNA polymerase using the H1-
RNA gene promoter. As a negative control for our experi-
ments, we used siRNA targeted to EBNA1 region of EBV.
The effects of siRNA on the expression of green fluores-
cence protein from the IRES clones were examined by co-
transfection experiments in Huh-7 cells. Initially, transfec-
tion experiments were performed to determine the opti-
mum ratio of pSuper-retro siRNA and HCV IRES GFP
plasmid for obtaining maximum inhibition of GFP from
the IRES 1b clone. A ratio of 1:4 (one 100 nanogram of
HCV-IRES-GFP and 400 nanogram of siRNA plasmid)
produced the maximum inhibition. Using a similar exper-
imental condition, the antiviral effect of four different
siRNA targets on translation of individual HCV IRES GFP
chimeric clone was examined. The specific inhibitory
effect of siRNA on GFP expression was quantitated by flow
cytometry analysis. The silencing of green fluorescence
expression from different HCV IRES clones by four differ-
ent siRNAs constructs is shown in Fig. 2. The siRNA-74
targeted to the stem loop II of HCV IRES was most effi-
cient and completely silenced the expression of GFP in the
case of all genotypes of HCV tested, siRNA-174 and
siRNA-207 were moderately effective and siRNA-245 was
the least effective. All three siRNA 74,174 and 207 effec-
tively silenced expression of GFP from HCV 1a and
HCV1b genotypes. These are the two most common gen-
otypes of HCV in the United States that frequently
develop resistance to interferon and ribavirin combina-
tion therapy. A control siRNA targeted to the Epstein Barr
Virus nuclear antigen 1 (EBNA1) did not inhibit GFP
expression in these experiments, indicating that the anti-
viral action of siRNA mediated gene silencing is highlyVirology Journal 2006, 3:100 http://www.virologyj.com/content/3/1/100
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specific. The numbers of GFP expressing Huh-7 cells after
siRNA transfection was quantitatively measured by flow
analysis (Fig. 3). It was determined that siRNA74 inhib-
ited the IRES-GFP expression in approximately 80 to 90%
of transfected Huh-7 cells in the case of all genotypes of
HCV. Other siRNAs 174, 207 and 245 transfection inhib-
ited GFP expression in only 40–60% of cells. The control
siRNA specific to EBNA1 did not have any effect on GFP
expression.
Intracellular delivery of siRNA74 inhibits expression of full-
length clones of HCV 1a and 1b
The majority of chronic hepatitis C patients in the US are
infected with HCV 1a or HCV1b genotypes, two geno-
types of HCV that frequently develop resistance to inter-
Location of siRNA targets to the 5'UTR of HCV genome Figure 1
Location of siRNA targets to the 5'UTR of HCV genome. Predicted secondary structure of the 5' UTR sequences (18–357). 
The sequence shown is that of the genotype 1a 5'UTR, HCV-H [40], and the structure based on previous studies [41-43]. 
Stem-loop structures are labeled for reference. The chimeric clones were made by fusing the GFP-encoding sequence, includ-
ing a poly (A) tail, after the CCU sequence of the 5'UTR by overlapping PCR. The locations of siRNA targets in the stem-loop 
regions are shown by arrows.Virology Journal 2006, 3:100 http://www.virologyj.com/content/3/1/100
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feron and ribavirin combination therapy. We tested
whether this highly effective siRNA-74 target in the 5' UTR
region could silence the gene expression using full-length
infectious clones of HCV1a and HCV1b. One HCV1a
infectious clone (pCV-H77C) and two HCV1b infectious
clones of HCV (pMO9.6-T7 and pCVJ4L6S) were used as
targets [26-28]. To examine the antiviral effect of siRNA-
74, each full-length clone were co-transfected with
increasing concentration of siRNA plasmid using a two-
step transfection procedure described earlier (37–38). The
inhibition of core protein expression of full-length clones
of HCV 1a and HCV1b due to siRNA transfection was
determined by immunoperoxidase staining (Fig. 4). Com-
plete silencing of core protein expression was seen in
Huh-7 cells transfected with HCV full-length clone 1a
(pCV-H77C) and 1b (pMO9.6-T7 and pCVJ4L6S). This
effect appears to be very specific since cells transfected
with control siRNA targeted to EBNA1 silencing of core
protein was not observed. Protein lysates were made and
Western blot analysis was performed using the same mon-
oclonal antibody specific for the HCV core protein. These
results suggest that siRNA-74 effectively silenced gene
expression from infectious full-length clones of HCV1a
and HCV1b genotypes(Fig. 5). We then examined
whether the silencing of core protein expression in the
transfected cells caused intracellular degradation of HCV
genomic RNA. Total RNA was isolated from the trans-
fected cells and digested with DNaseI to eliminate plas-
mid DNA carryover from the transfection. The levels of
positive strand HCV RNA were measured by ribonuclease
protection assay (RPA). The results shown in suggest that
siRNA74 degraded HCV positive- strand HCV RNA in a
dose dependent manner in all clones (Fig. 6). Specificity
of this silencing mechanisms occurring due to intracellu-
lar RNA degradation was examined by measuring HCV
RNA levels in the cells co-transfected with control siRNA
(EBNA1). These differences are not due to the variation of
HCV RNA in the nucleic extracts since GAPDH mRNA lev-
els are comparable in all samples. Taken together the
results of our analysis suggest that siRNA-74 targeted to
the 5'UTR region can inhibit IRES mediated translation of
Effect of small interfering RNAs on the expression of green fluorescent protein from IRES clones of six different HCV geno- types Figure 2
Effect of small interfering RNAs on the expression of green fluorescent protein from IRES clones of six different HCV geno-
types. Huh-7 cells were co-transfected with HCVIRES-GFP plasmid with siRNA plasmid (pSuper-retro) by using the FuGENE 6 
transfection reagent. After 48 hours transfected cells were observed under a fluorescence microscope. The experiments were 
repeated for each genotype IRES clones using different siRNA constructs. SiRNA-74 was the most effective and inhibited the 
expression of green fluorescence in all genotypes of HCV compared to other siRNA. Control siRNA targeted to EBNA1 had 
no effect on GFP expression from HCV IRES clones.Virology Journal 2006, 3:100 http://www.virologyj.com/content/3/1/100
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HCV and also are highly effective in silencing the gene
expression of HCV 1a and HCV 1b strain.
Discussion
Chronic HCV infection usually treated with a combina-
tion of pegylated interferon-alpha and ribavirin. How-
ever, the majority of chronic hepatitis C patients in the
United States develop cellular resistance to interferon
therapy. There is a need to develop new antiviral
approaches to inhibit HCV replication. At present, there
are several antiviral strategies that have been employed to
inhibit HCV virus replication [29]. Among these, RNA
interference appears to be one of the most powerful anti-
viral approaches to inhibit HCV gene expression in mam-
malian cells. RNA interference (RNAi) is a sequence
specific RNA degradation process in the cytoplasm of
eukaryotic cells induced by double-stranded RNA [30,31].
This process can be initiated via so called small interfering
RNAs (siRNA) of approximately 19–23 base pairs. These
are cleaved by double-stranded precursor RNAs by the
RNase III-like enzyme dicer. These siRNAs associate with
various proteins to form the RNA-inducing silencing com-
plex (RISC), harboring nuclease and helicase activity. The
antisense strand of the siRNA guides the RISC to the com-
plementary target RNA and the nuclease component
cleaves the target RNA in a sequence specific manner. This
approach has been a widely used as a technique for gene
knockouts for gene expression studies and as an antiviral
against a number of viruses [32-34]. The RNAi approach
is very specific and offers a great potential to be used as
antiviral against hepatitis C virus infection. Reports from
the previous studies including our own experience suggest
that this siRNA-based approach is very effective by yield-
ing up to 100-fold inhibition of virus replication [14-20].
We have used siRNA targets in the E2, NS3 and NS5B
region and showed that these siRNA targets can silence
HCV 1a infectious clone effectively. However, the same
siRNA does not work effectively against other viral strains,
because of sequence variation in the siRNA target. To
develop siRNA targets that can be used for both HCV 1a
Quantitative measurement of GFP positive Huh-7 cells by flow cytometry after siRNA transfection Figure 3
Quantitative measurement of GFP positive Huh-7 cells by flow cytometry after siRNA transfection. Huh-7 cells were co-trans-
fected with HCVIRES-GFP plasmid with siRNA plasmid (pSuper-retro) by using the FuGENE 6 transfection reagent. After 48 
hours of transfection, cells were harvested and GFP positive cells were analysed by a flow cytometer (Becton Dickinson, BD 
Biosciences, Clontech). Percentage of GFP-positive Huh-7 cells was quantitatively determined after siRNA transfection using 
cell quest computer software. The results were expressed as percentage of control. siRNA-74 was found to be most effective 
in silencing GFP from all IRES clones.Virology Journal 2006, 3:100 http://www.virologyj.com/content/3/1/100
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and HCV1b virus and other genotypes we selected the
highly conserved region of HCV. The 5' untranslated
region (UTR) of HCV consisting of 341 nucleotides, is
highly conserved among different viral genotypes and in
clinical strains of HCV [35]. We selected four siRNA tar-
gets in the second and third stem-loop regions of second-
ary structure of 5'UTR. To direct the synthesis of fully
processed siRNA-like transcripts in transfected Huh-7 cells
a mammalian expression plasmid vector (pSuper-retro)
was used. The use of the vector-based delivery is more effi-
cient because it allows continuous transcription of siRNA
in the transfected cell. We showed that intracellular
Immunocytochemical staining showing the silencing of core protein from full-length clones of HCV by siRNA-74 Figure 4
Immunocytochemical staining showing the silencing of core protein from full-length clones of HCV by siRNA-74. Huh-7 cells 
were co-transfected with (10 μg) pSuper-retro-siRNA74 and (10 μg) full-length clones of HCV. After 48 hours, transfected 
cells were harvested by the treatment with trypsin-EDTA. Cells were washed with PBS and immobilized onto a glass slide by 
cytospin method. Then slides were blocked and stained with core antibody against HCV using a mouse monoclonal antibody. 
Immunostaining for HCV core protein was performed using a standard protocol. The expression of core protein of full-length 
HCV 1a (pCVH77C), Ib (pCVJ4L6S), and 1b (pMO9.6--T7) is observed in the presence of siRNA74 and siRNAEBNA1 (unre-
lated siRNA).Virology Journal 2006, 3:100 http://www.virologyj.com/content/3/1/100
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expression of siRNA silences GFP expression from IRES
clones. Some of the siRNA targets appear to be more effi-
cient than others. For example, siRNA-74 is found to be
most effective against six different viral IRES sequences as
compared to the other three. The siRNA-174, siRNA-207
is moderately effective against HCV 1a and HCV 1b IRES.
The siRNA-254 was the least effective against HCV1a and
HCV1b IRES, but it was highly effective against 2b, 3a, 4a
IRES. The results could be due to the fact that there are
some nucleotide variations in the IRES sequences among
different virus genotypes. There are also published reports
suggesting that many cellular proteins binds to the 5' UTR
sequence of HCV for translation of polyprotein. It is pos-
sible that the some siRNAs could not have efficiently
hybridize to some sequences in the transfected cells than
the others because of complex secondary structure of the
5'UTR.
We extended this study and examined whether the siRNA-
74 could also effectively silence gene expression of HCV
1a and 1b strain. We used full-length chimpanzee infec-
tious clones as viral targets. The full-length HCV genomic
clone was expressed in Huh-7 cells by the use of adenovi-
rus T7 RNA polymerase. We have shown that this induci-
ble model allows high-level expression of HCV structural
and non-structural proteins that can be measured by
Western blot analysis (37,38). Replication of HCV full-
length genome 1a and 1b was observed in the transfected
hepatic cell lines by detecting viral negative strand RNA by
strand specific ribonuclease protection assay. Using co-
transfection studies, it was determined that complete
silencing of HCV core protein expression was observed by
siRNA-74 for HCV 1a and HCV 1b infectious clones. The
inhibition of viral protein expression by siRNA-74 was
confirmed by an immunocytochemical method as well as
by Western blot analysis. No inhibition was seen in the
cells co-transfected with unrelated siRNA, suggesting that
the antiviral effect of siRNA-74 is specific. These results
were confirmed by looking at the stability of full-length
HCV genomic RNA in the transfected cells by RPA. Silenc-
Western blot analysis showing the silencing of core protein from full-length clones of HCV by siRNA transfection Figure 5
Western blot analysis showing the silencing of core protein from full-length clones of HCV by siRNA transfection. Huh-7 cells 
were co-transfected with pSuper-retro-siRNA74 and full-length clones of HCV using the FuGENE 6 reagent. After 48 hours, 
transfected cells were isolated by the treatment with trypsin-EDTA. Cells were washed once with PBS and protein lysates 
were prepared and electrophoresed on 10% SDS-PAGE gels. The proteins were transferred to nitrocellulose membranes, 
blocked and immunoreacted with a primary antibody. The membrane was washed and incubated with peroxidase labeled sec-
ondary antibody and developed by ECL-chemiluminescence method. siRNA74 inhibited the expression of core protein in the 
case of all three full-length clones of HCV 1a and 1b. Beta actin levels were used as a control to make sure that equal amount 
of protein was present in the extracts.Virology Journal 2006, 3:100 http://www.virologyj.com/content/3/1/100
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ing of the viral protein expression was due to the specific
degradation of HCV genomic mRNA. Our results clearly
support the hypothesis that the siRNA-74 can cause gene
silencing of HCV1a and HCV1b strains. In summary,
these results clearly show that the siRNA mediated viral
gene silencing is a very effective antiviral strategy that has
a very strong potential for curing chronic hepatitis C virus
infection. The siRNA-74 is an important therapeutic target
for the treatment of infection of multiple genotypes of
HCV.
Conclusion
In the present study we identified a siRNA targeted to the
stem loop II (siRNA-74) of 5'UTR of HCV that inhibited
the expression of GFP in six different chimeric clones of
HCV as well as inhibited the expression of the core protein
and degraded the positive strand RNA in full-length
clones of HCV 1a and 1b. Therefore, our results support
that use of the siRNA74 as an important target for inhibit-
ing IRES mediated translation of multiple genotypes of
HCV.
Methods
Cell line and Transcription plasmid
Huh-7 cell line was maintained in Dulbecco's Modified
Media (D-MEM) containing non-essential amino acids,
sodium pyruvate and 10% fetal bovine serum (In vitrogen
Life Technologies, Carlsbad, CA). Chimeric clones
between IRES sequences of six different HCV genotypes
and green fluorescence protein used here were con-
structed previously [36]. A chimpanzee infectious clones
pCV-H77C (HCV1a) was obtained from Jens Bukh,
National Institute of Health [26,27]. Full-length HCV
transcription plasmid (pNIH1a-Rz) was prepared using
chimpanzee infectious clone (pCV-H77C), which con-
tains a T7 promoter, full-length cDNA of HCV genome,
followed by a cDNA copy of autolytic ribozyme from
antigenomic strand of hepatitis delta virus and T7 tran-
scriptional terminator sequences. Detailed description of
transcription plasmid and method has been described
previously [37,38]. A chimpanzee infectious clone
(pCVJ4L6) was obtained from Jens Bukh, National Insti-
tute of Health. Transcription plasmid (pTRE-NIH1b) was
prepared by addition of hepatitis delta virus ribozyme
sequences and T7 transcriptional terminator at the very
end of 3'UTR using the methods described in our publica-
tions. A chimpanzee infectious clone pMO9.6-T7
Ribonuclease protection assay showing siRNA expression specifically degraded intracellular HCV positive strand RNA in the  transfected Huh-7 cells Figure 6
Ribonuclease protection assay showing siRNA expression specifically degraded intracellular HCV positive strand RNA in the 
transfected Huh-7 cells. Huh-7 cells were co-transfected with different concentration of siRNA74 with different full-length 
clones of HCV. After 48 hours, transfected cells were isolated by the treatment with trypsin-EDTA. Total RNA was isolated 
and subjected to RPA for positive strand HCV using a minus strand RNA probe targeted to the 5'UTR region. The degradation 
of HCV positive strand by siRNA74 is concentration dependent. No HCV RNA degradation was observed in the cells trans-
fected with unrelated siRNA.Virology Journal 2006, 3:100 http://www.virologyj.com/content/3/1/100
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(HCV1b) containing an autolytic ribozyme sequence
from antigenomic strand of hepatitis delta virus and T7
transcriptional terminator sequences at the 3' end was
used here as described previously [37,38].
Construction of pSuper-retro vector encoding siRNAs
Four different siRNAs were selected and targeted to the 5'
UTR region of HCV genome (1b) using web-based Oligo-
Engine software. As a control, siRNA targeted to Epstein
barr virus (EBV) nuclear antigen was used [39]. A com-
mercially available plasmid vector called pSuper-retro
(Oligo- Engine) for intracellular delivery of siRNA was
used. The siRNA constructs were prepared at two steps. In
the first step, we synthesized a pair of (sense and anti-
sense orientation) 64-nts oligos containing 19 nucle-
otides of HCV in sense and antisense orientations, sepa-
rated by a 9-nt spacer sequence. Restriction enzymes Xho1
and Bgl II were introduced at the 5' end of sense and anti-
sense 64 nucleotide oligos for cloning. In the second step,
the sense and antisense primers were annealed by incuba-
tion at 90°C for 4 min then 72°C for 10 minutes. The
annealed oligos were then slowly cooled to 10°C and
ligated to the pSuper-retro vector using Xho1 and Bgl II
restriction sites. The nucleotide sequences of the sense and
antisense primer used to design the siRNA vectors are
shown in Table 1. The recombinant clones containing the
iRNA insert were selected by restriction enzyme digestion.
Large-scale plasmid DNA isolation was performed using a
maxi kit (Qiagen Inc). The presence of siRNA sequences
was confirmed by DNA sequence analysis.
Effect of siRNA on expression of GFP from different IRES 
clones
Huh-7 cells were grown in a 12- well tissue culture dish
the day before transfection. The next day the cells were
infected with a replicative defective adenovirus that
expressed T7 RNA polymerase. After two hours, cells were
co-transfected with 100 ng of HCV-IRES-GFP plasmid and
different concentrations siRNAs plasmid using FuGENE 6
reagent (Roche Molecular Biochemicals, Indianapolis,
IN). Expression of green fluorescence was recorded at 24,
48 and 72 hours using a fluorescence microscope. The
ratio of IRES plasmid to siRNA-74 plasmid required for
maximum inhibition of GFP expression from the IRES
clone was recorded. Using the identical condition effect of
four different siRNAs on GFP expression from IRES clone
was examined. The inhibitory effects of each siRNA plas-
mid on GFP expression from six different HCV IRES
sequences were quantitatively by flow analysis. Trans-
fected cells were harvested by treatment with trypsin-
EDTA, and then resuspended in PBS (Invitrogen Life Tech-
nology, Carlsbad, CA) and subjected to flow-cytometric
analysis (Becton Dickinson, BD Biosciences Clontech).
The percentage of GFP-positive Huh-7 cells was quantita-
tively compared with control siRNA for different siRNA
with different HCV genotypes.
Effect of siRNA on expression of full-length HCV genome
To examine the effect of siRNA on expression of full-
length HCV 1a and 1b strain was examined by co-transfec-
tion experiments. We have developed a T7- based model
in which expression of full-length HCV RNA genome can
be reliably studied in Huh-7 cells. Detailed methodology
has been described previously [37,38]. Huh-7 cells were
co-transfected with 10 micrograms of HCV full-length
plasmid and different concentration siRNAs plasmid
using FuGENE 6 reagent. The success of intracellular deliv-
ery of each siRNA targets against full-length HCV 1a and
HCV1b strain was examined by measuring core protein
and positive strand HCV RNA.
Immunoperoxidase Staining
The extent of core protein inhibition due to siRNA74 on
full-length clones of HCV1a and 1b was examined by
immunostaining of transfected Huh-7 cells using a mon-
oclonal antibody (Affinity Bioreagents, Denver. CO).
Transfected Huh-7 cells were immobilized onto glass
slides by cytospin method. Cells were washed with phos-
phate-buffered saline (PBS) pH 7.4 twice, air-dried and
fixed with chilled acetone for five minutes. The cells were
permeabilized by treatment with 0.05% saponin for 10
minutes at room temperature. Blocking was performed
with 5% normal goat serum (Sigma Chemical Company,
St. Louis, MO) diluted in minimum essential medium for
30 minutes at room temperature. Blocking for endog-
enous biotin-avidin was performed using blocking rea-
Table 1: Sequences of small interfering RNAs used to target the 5' UTR of hepatitis C virus RNA
Name of the siRNA Nucleotide sequence
siRNA 74 S 5'-AGCGTCTAGCCATGGCGTT-3'
siRNA74 AS 3'-TCGCAGATCGGTACCGCAA-5'
siRNA174 S 5'-TTGCCAGGATGACCGGGTC-3'
siRNA174 AS 3'-AACGGTCCTACTGGCCCAG-5'
siRNA207 S 5'-CCCGCTCAATGCCTGGAGA-3'
siRNA207 AS 3'GGGCGAGTTACGGACCTCT-5'
siRNA245 S 5'-GACTGCTAGCCGAGTAGCG-3'
siRNA245 AS 3'-CTGACCATCGGCTCATCGC-5'Virology Journal 2006, 3:100 http://www.virologyj.com/content/3/1/100
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gents from the kit (Avidin/Biotin Blocking Kit, Vector
Laboratories Inc., Burlingame, CA) and blocking for
endogenous peroxidase was done with 0.9% H2O2 for 30
minutes at room temperature. The cells were incubated
with monoclonal anti-core antibody (1:100 dilution)
overnight at 4°C. The next day they were washed three
times and incubated with anti-mouse biotin conjugated
antibody (1:1000) for one hour at room temperature. The
slides were washed and incubated for 30 minutes with
Elite avidin-biotin peroxidase complex (VECTOR Labs,
CA). The slides were then reacted with diaminobenzidine
for 10 minutes and then counterstained with hematoxylin
for one minute. After dehydration, the slides were
mounted with permount and observed under light micro-
scopy.
Western Blot Analysis
Western blot analysis for core protein was performed on
protein lysate from transfected cells using a standard pro-
tocol in our laboratory [37,38]. Briefly, transfected cells
were treated with 500 μl of lysis buffer containing 150
mM sodium chloride, 50 mM Tris-HCl, 1% NP-40, 0.5%
deoxycholate, 0.1% SDS and protease inhibitors (Protease
Inhibitor Cocktail, Roche Biochemicals, Indianapolis,
IN). Fifty micrograms of the total cell lysate was separated
by 10% SDS-PAGE and transferred onto nitrocellulose
membranes (Amersham, Arlington Heights, and IL). The
membranes were blocked with PBS containing 5% non-
fat dried milk and 0.1% Tween-20 for 1 hour at room tem-
perature. Then, the membrane was incubated with mono-
clonal antibody against core (Affinity Bioreagents,
Denver, CO) at 1:100 dilutions for one hour. The mem-
brane was washed three times with 0.1% Tween-20 in
PBS. Following this step, the membranes were incubated
with peroxidase-labeled secondary antibody (ECL West-
ern blotting analysis system, Amersham Pharmacia Bio-
tech UK, Amersham PLC, Buckinghamshire, England) at a
dilution of 1:1000 for one hour. After this step, mem-
branes were washed three times with PBS and developed
using ECL Chemiluminescence Detection Kit (Amersham
Pharmacia Biotech UK, Amersham PLC, and Bucking-
hamshire, England). To verify that equal amounts of pro-
tein were loaded onto each lane of the SDS-PAGE, the
membrane was incubated with monoclonal antibody to
beta-actin.
Ribonuclease Protection Assay (RPA)
Levels of HCV genomic RNA (positive strand) in the
siRNA-transfected cells were examined by RPA. Total RNA
was isolated from the transfected cells by the GITC
method. RNA extracts were treated with DNase I (Roche
Molecular Biochemicals, Indianapolis, IN) 5U/mg of RNA
for one hour at 37°C to remove any residual plasmid
DNA templates. RPA was performed to detect the presence
of HCV-positive in transfected Huh-7 cells (Ambion, Aus-
tin, TX). The RNA probe targets the highly conserved 5'
UTR of HCV genome. The plasmid pCR II-296 was linear-
ized with Xba I and used to prepare an anti-sense RNA
probe using the SP6 RNA polymerase in the presence of
32P-UTP. For RPA assays, approximately 1 × 106 cpm of
the labeled anti-sense probe was added to 25 μg of RNA
sample and vacuum dried. Hybridization was performed
in 10 μl of the hybridization buffer after denaturing for 3
minutes at 95°C and followed by overnight incubation at
45°C. RNase digestion was performed in 200 μl of RNase
cocktail (1: 100) (Ambion Inc. Austin, Texas) in a buffer
consisting of 10 mM Tris, pH 7.5, 5 mM EDTA and 0.3 M
NaCl for 1 hour at 37°C. Reactions were stopped by the
addition of 2.5 μl of 25% SDS and 10 μl of proteinase K
(10 mg/ml) at 37°C for 15 minutes. Samples were
extracted with phenol/chloroform and precipitated with
ethanol. The pellet was air dried and resuspended in 15 μl
of gel loading buffer. The samples were then boiled for 3
minutes and separated on an 8% acrylamide/8 M urea gel.
The gel was dried and exposed to X-ray film (Kodak, X-
OMAT-AR).
List of abbreviations
HCV, hepatitis C virus; RNAi, RNA interference; siRNA,
small interfering RNA, dsRNA, double stranded RNA;
IRES, internal ribosome entry site; GFP, Green fluores-
cence protein.
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